Table 3.

Clinical trials of the adenovirus-based oncolytic viruses

Oncolytic vector	Therapeutic agent	Cancer type	Phase, study type	Mode of therapy	Purpose of the study	Status	Clinical trial number
DNX2401	DNX2401 in combination with temozolomide	Recurrent glioblastoma	Phase 1, open-label, single-group study	Intra-tumoral	Safety evaluation	Completed	NCT01956734
	DNX2401 with interferon gamma	Recurrent glioblastoma	Phase 1b, open-label, parallel assignment	Intra-tumoral	Efficacy evaluation of DNX-2401	Completed	NCT02197169
	DNX-2401	Diffuse pontine glioma	Phase 1, open-label, single-group study	Intra-tumoral	Safety evaluation and dose determination	Recruiting	NCT03178032
	DNX-2401 in combination with pembrolizumab	Recurrent glioblastoma or gliosarcoma	Phase 2, multicenter, open-label study	Intra-tumoral DNX-2401 with intravenous pembrolizumab	Single dose efficacy evaluation of DNX-2401	Active, not recruiting	NCT02798406
ONCOS-102	ONCOS-102 in combination with cyclophosphamide	Advance cancers, malignant solid tumor	Phase 1, open-label, single-group study	Intra-tumoral ONCOS-102 with intravenous cyclophosphamide	Safety and dosage determination	completed	NCT01598129
	ONCOS-102 in combination with pemetrexed/cisplatin or cyclophosphamide	Un-resectable malignant pleural mesothelioma	Randomized phase 1b or phase2 open-label, parallel group-study	Intra-tumoral ONCOS-102	Evaluation of safety, tolerability and efficacy of ONCOS-102 in combination with chemotherapy	Active, not recruiting	NCT02879669
	ONCOS-102 in combination with pembrolizumab or cyclophosphamide	Advanced or un-resectable melanoma	Phase1, open-label, single-group study	Intra-tumoral ONCOS-102 with intra-venous pembrolizumab	Safety evaluation of sequential treatment with ONCOS-102 in combination with pembrolizumab	Recruiting	NCT03003676
VCN-01	VCN-01 in combination with gemcitabine and Abraxane	Patients with advanced solid tumors	Phase1, open-label, single-group study	Intra-venous administration of VCN-01 with gemcitabine	Safety and tolerability evaluation of VCN-01 in combination therapy	Active, not recruiting	NCT02045602
	VCN-01	Refractory retinoblastoma	Phase 1, open-label, single-group study	Intra-vitreal injection of VCN-01	Safety and efficacy evaluation	Recruiting	NCT03284268
	VCN-01 in combination with durvalumab	Recurrent head and neck squamous cell carcinoma	Phase 1, multicenter, open-label, dose-escalation study	Intra-venous injection of VCN-01 and durvalumab	Safety, tolerability and efficacy evaluation	Recruiting	NCT03799744
LOAd703	LOAd703 in combination with gemcitabine and nab-paclitaxel	Pancreatic cancer	Open-label, single-group phase 1/2 trial	Ultra-sound guided percutaneas injection of LOAd703	Safety evaluation	Recruiting	NCT02705196
	LOAd703	Pancreatic, ovarian, biliary and colorectal cancer	Open-label, single-group, phase 1/2 study	Image-guided intra-tumoral injection of LoAd703	Evaluation of efficacy of LOAd703 in various cancers	Recruiting	NCT03225989
ColoAd1	ColoAd1	Resectable colon cancer, resectable non-small cell lung cancer, bladder cancer, renal cell carcinoma	Phase 1 study	Intra-tumoral injection or intravenous infusion of ColoAd1	Mechanism of action study	Completed	NCT02053220
	ColoAd1	Solid tumor of epithelial origin, colorectal cancer, bladder cancer	Phase I, Phase II study	Sub-acute fractionated intravenous injection	Dose escalation study	Completed	NCT02028442
OBP-301	Telomelysin (OBP-301)	Esophago gastric adenocarcinoma	Phase 2 study	Intra-tumoral	Safety and efficacy study	Recruiting	NCT03921021
	OBP-301 and pembrolizumab	Advanced solid tumor	Phase 1 study	Intra-tumoral	Safety and efficacy study	Recruiting	NCT03172819
	OBP-301	Hepatocellular carcinoma	Phase 1 study	Intra-tumoral	Safety and efficacy study	Recruiting	NCT02293850
	OBP-301	Melanoma Stage III/IV	Phase 2 study	Intra-lesion	Safety, efficacy evaluation	Active but not recruiting	NCT03190824
CG0070	CG0070	Bladder cancer (BOND2)	Phase 2 study	Intra-vesical therapy	Safety and efficacy study	Completed	NCT02365818
	CG0070	Bladder cancer (ExBOND)	Phase 2 study	Intra-vesical therapy	Safety and efficacy study	Withdrawn	NCT02143804
	CG0070	Carcinoma, transitional cell bladder neoplasms	Phase 1 study	Intra-vesical therapy	Evaluation of safety and dosing of CG0070	Current recruitment status is unknown	NCT00109655